FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Published:2016-07-12 Issue:20 Volume:22 Page:4968-4972
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Walker Amanda J.,Wedam Suparna,Amiri-Kordestani Laleh,Bloomquist Erik,Tang Shengui,Sridhara Rajeshwari,Chen Wei,Palmby Todd R.,Fourie Zirkelbach Jeanne,Fu Wentao,Liu Qi,Tilley Amy,Kim Geoffrey,Kluetz Paul G.,McKee Amy E.,Pazdur Richard

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

2. Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies;Endocrinology;2024-04-21

3. A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells;Acta Biomaterialia;2024-03

4. PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors against Metastatic Cutaneous Squamous Cell Carcinoma In Vitro;Cancers;2024-01-15

5. Deconstructing the Contributions of Heterogeneity to Combination Treatment of Hormone-Sensitive Breast Cancer;The IMA Volumes in Mathematics and its Applications;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP